

# Manuel castro-fernandez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5441296/publications.pdf>

Version: 2024-02-01

22  
papers

888  
citations

516561

16  
h-index

580701

25  
g-index

28  
all docs

28  
docs citations

28  
times ranked

868  
citing authors

#	ARTICLE	IF	CITATIONS
1	Room for Improvement in the Treatment of Helicobacter pylori Infection. Journal of Clinical Gastroenterology, 2022, 56, e98-e108.	1.1	36
2	Vedolizumab-induced cholestatic liver injury. Gastroenterology Y Hepatology, 2022, 45, 64-65.	0.2	1
3	European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21,533 patients. Gut, 2021, 70, 40-54.	6.1	139
4	Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). American Journal of Gastroenterology, 2021, 116, 1220-1229.	0.2	40
5	European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics, 2021, 10, 13.	1.5	12
6	V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterology Y Hepatology (English Edition), 2021, , .	0.0	0
7	Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H. pylori management (Hp-EuReg). Helicobacter, 2020, 25, e12686.	1.6	27
8	Modulation of faecal metagenome in Crohn's disease: Role of microRNAs as biomarkers. World Journal of Gastroenterology, 2018, 24, 5223-5233.	1.4	26
9	IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterology Y Hepatology (English Edition), 2016, 39, 697-721.	0.0	27
10	IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterology Y Hepatology, 2016, 39, 697-721.	0.2	97
11	Remission maintained by monotherapy after biological+ immunosuppressive combination for Crohn's disease in clinical practice. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 112-118.	1.4	10
12	Prognosis of Patients with Ulcerative Colitis in Sustained Remission After Thiopurines Withdrawal. Inflammatory Bowel Diseases, 2015, 21, 1564-1571.	0.9	23
13	Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy. Digestive Diseases and Sciences, 2015, 60, 458-464.	1.1	42
14	Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 291-295.	1.4	36
15	Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection. Journal of Clinical Gastroenterology, 2013, 47, 130-135.	1.1	60
16	Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. Journal of Crohn's and Colitis, 2011, 5, 608-611.	0.6	9
17	Cronkhite-Canada syndrome: a new case report of this enigmatic and infrequent disease. Revista Española De Enfermedades Digestivas, 2010, 102, 208-15.	0.1	1
18	Recurrence of Helicobacter pylori Infection: 3650 Patient-years Follow-up Study. Helicobacter, 2008, 13, 388-388.	1.6	7

#	ARTICLE	IF	CITATIONS
19	Electronic Clinical Challenges and Images in GI. <i>Gastroenterology</i> , 2008, 135, e6-e7.	0.6	1
20	Second-Line Rescue Therapy With Levofloxacin After H. pylori Treatment Failure: A Spanish Multicenter Study of 300 Patients. <i>American Journal of Gastroenterology</i> , 2008, 103, 71-76.	0.2	79
21	Coexistence of Pyoderma Gangrenosum and Sweet's Syndrome in a Patient With Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2007, 102, 2865-2866.	0.2	19
22	Third-Line Rescue Therapy with Levofloxacin After Two H. pylori Treatment Failures. <i>American Journal of Gastroenterology</i> , 2006, 101, 243-247.	0.2	98